A coalition of Thai civil society groups has written a letter opposing Gilead’s patents for the fixed-dose combination of AVR tenofovir and emtricitaine (TDF+FTC, sold under the brand name Truvada), an important first-line therapy for the treatment of HIV/AIDS. The letter opposes the granting of the patent because it would not meet the criteria for patentability found in the Thai Patent Act, novelty, inventive step, and capability of industrial application. Says the letter “TDF is not a newly invented drug… and its combination requires no high technology to prove significant inventive steps.”
Additionally, the letter warns that many evergreening patents have been issued in Thailand. It cites a study of all pharmaceutical patents granted between 2000 and 2010, which found that 90% of the patents granted failed to meet the criteria for patentability.
Thai Civil Society Letter Opposing TDF+FTC Patent Application
QUT Media4th November 2025 The United Kingdom Parliament is considering a bill aimed at making smoking obsolete, which has been
Speaking at the Global Expert Network on Copyright User Rights Symposium on 16 June 2025, Professor Christophe Geiger argues for
On 25 September 2025, Professor Wend Wendland, delivered the 14th Peter Jaszi Distinguished Lecture at American University in Washington D.C..
On September 18, 2025, the Italian Senate definitively approved the country’s first comprehensive framework law on artificial intelligence (AI). The
Por Andrés Izquierdo Durante la segunda semana de agosto, fui invitado a hablar en la Feria Internacional del Libro de
By Andrés Izquierdo AI, Copyright, and the Future of Creativity: Notes from the Panama International Book FairDuring the second week